Singapore, Aug. 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Aaron Tan Chia-Ken
Dr Chia Puey Ling
Published by HT Digital Content Services with permission from Health Daily Digest....